A long-term agreement between the Siemens technology group and Sartorius Stedim Biotech (SSB) provides that SSB will preferably use Siemens automation technologies, including industrial PCs, the S7-1500 software controller, the TIA Portal and the SCADA system Simatic WinCC, among others.
The hardware and software components will be employed in many products and solutions that SSB offers its customers for the development and manufacture of biopharmaceuticals, such as vaccines and monoclonal antibodies.
Sartorius Stedim Biotech has been using established Siemens automation solutions for process control in its large-scale bioreactor and filtration systems for quite some time. To standardise its own product portfolio even further, SSB has decided to introduce a new, configurable automation system for its range of systems. Under the recently concluded agreement, cooperation between the two companies will therefore be extended to further Sartorius Stedim Biotech products.
These will be successively equipped with Siemens automated solutions in the coming months and can thus be integrated into process control systems, such as Simatic PCS 7 and Simatic Batch. Essentially, such SSB products are single-use bioreactors of the BIOSTAT STR series, various filtration systems and the FlexAct system. The latter is a flexible module that is used to control many different process steps within biopharmaceutical production.
“By introducing this new automation platform and further standardising our products, we are making it easy for our customers to integrate their systems into higher-level automation solutions, such as SCADA, MES or ERP. At the same time, we are enabling them to achieve easier scalability of processes ranging from lab scale to commercial-scale production,” explained Dr. Oscar-Werner Reif, Chief Technology Officer at Sartorius Stedim Biotech. “We have found an ideal partner in Siemens as one of the leading companies in automation,” continued Dr. Reif.
Eckard Eberle, CEO of the Siemens Process Automation business unit, commented: “We are happy to support Sartorius Stedim Biotech with our unique and cohesive portfolio consisting of hardware, software and service throughout the entire system life cycle. Based on our cooperation, users in the biopharmaceutical industry stand to benefit from higher efficiency, quality and flexibility, as well as faster time to market.”
